Evan Tallmadge advises clients across the life sciences ecosystem in negotiating complex licenses, collaboration agreements, co-commercialization and co-promotion agreements, supply agreements, software licenses, and other bespoke contracts. He represents mature pharmaceutical companies, growth-stage biotech companies, hospitals, academic institutions, and private equity funds on both the licensor and licensee side of transactions.

Evan’s pro bono practice focuses on advising student organizations and non-profit organizations on IP and contracting matters, including advising Artists for Humanity in the negotiation of contracts for public art installations.

During law school, Evan was the executive editor of the Harvard Journal of Law and Technology. His graduate research at Cornell University in the lab of David B. Collum was on the solution structures and kinetics of the lithium enolates of acylated 2-oxazolidinones. 


Licensing and Strategic Transactions

  • Represented Mammoth Biosciences, Inc. in a collaboration and license agreement with Regeneron Pharmaceuticals, Inc. for research and early-stage development of novel CRISPR/Cas gene editing therapies directed to Regeneron-selected targets, and for the clinical trials and commercialization of such products.
  • Represented Teva Pharmaceuticals International GmbH in a strategic global licensing agreement with mAbxience for a biosimilar candidate currently in development for the treatment of multiple oncology indications.
  • Represented Sanofi in negotiating a $1+ billion strategic collaboration with BioMap under which the parties would leverage BioMap’s AI engine and Sanofi’s deep biologics development experience to create advanced AI models and protein large language models for Sanofi to use to advance its novel biologic drug discovery and development pipeline.
  • Represented Pfizer in a novel strategic partnership with Flagship Pioneering to explore opportunities to develop 10 single-asset programs, with Pfizer having an option to acquire each development program and Flagship and its platform companies eligible to receive up to $700M in milestones and royalties for each successfully commercialized program.
  • Represented Adaptimmune Therapeutics in its $3+ billion strategic collaboration with Genentech to research, develop and commercialize cancer-target allogeneic T-cell therapies, under which the companies will combine their technologies and expertise to research and develop “off-the-shelf” cell therapies for up to five cancer targets and develop a novel allogeneic personalized cell therapy platform.
  • Represented Selecta Biosciences in an exclusive licensing and development agreement with Astellas Pharma for Xork, a potential next generation immunoglobulin G protease, that will be developed for use with Astellas’ AT845, an investigational, adeno-associated virus (AAV)-based treatment for Late-Onset Pompe disease (LOPD) in adults.
  • Represented a leading children’s hospital in a series of negotiations for a comprehensive overhaul of its IT systems, including a new electronic medical record system.
  • Represented TransMedics in a series of design and supply agreements for advanced medical device components.
  • Advised Northwell Health, New York’s largest healthcare provider, on the licensing of 3D print files for purposes of making adapters for ventilators to alleviate the COVID-19 crisis.
  • Represented a multinational pharmaceutical company in the negotiation of a clinical development agreement with an option to acquire the counterparty if the key drug candidate is successful.
  • Represented Sarepta Therapeutics, Inc. in a $1.15 billion exclusive license agreement with Roche to launch and commercialize Sarepta's investigational gene therapy for Duchenne muscular dystrophy outside the United States.
  • Represented a biopharmaceutical company in the negotiation of a clinical and commercial supply agreement with a key Chinese manufacturer.

Mergers & Acquisitions and Venture Capital

  • Advised The Vistria Group on intellectual property and licensing matters relating to a series of healthcare-related acquisitions, including Help at Home.
  • Advised Genstar Capital portfolio company Tekni-Plex on intellectual property and licensing matters related to a series of technology-related acquisitions.
  • Represented Eversource Energy and its subsidiary Aquarion Water Company in its acquisition of The Torrington Water Company.
  • Advised Charlesbank Capital Partners on its investment in Park Place Technologies.
  • Advised a private equity fund on intellectual property and licensing matters relating to its multi-billion dollar bid for a pharmaceutical company.
  • Advised an underwriter on intellectual property and licensing considerations for the IPO of a pharmaceutical company in the rare disease space.
  • Advised a private equity fund on licensing matters in its minority investment in an internet infrastructure company.

Areas of Practice